Form 8-K - Current report:
SEC Accession No. 0001610618-24-000146
Filing Date
2024-11-26
Accepted
2024-11-26 16:12:06
Documents
18
Period of Report
2024-11-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CIDARA THERAPEUTICS, INC. FORM 8-K cdtx-20241120.htm   iXBRL 8-K 42334
2 FORM OF PRE-FUNDED WARRANT ex412024-11x26.htm EX-4.1 124979
3 SECURITIES PURCHASE AGREEMENT ex1012024-11x26.htm EX-10.1 383857
4 REGISTRATION RIGHTS AGREEMENT ex1022024-11x26.htm EX-10.2 192231
5 PRESS RELEASE ex9912024-11x26.htm EX-99.1 10963
9 GRAPHIC cdtxlogoa18.jpg GRAPHIC 63449
  Complete submission text file 0001610618-24-000146.txt   1100694

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdtx-20241120.xsd EX-101.SCH 1780
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cdtx-20241120_lab.xml EX-101.LAB 22804
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cdtx-20241120_pre.xml EX-101.PRE 13048
20 EXTRACTED XBRL INSTANCE DOCUMENT cdtx-20241120_htm.xml XML 2829
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 241503844
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)